Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LNTH2403 Phase 1 dose, Phase 2; LNTH2403 a single agent recommended phase 2 dose
LNTH-2403 · 1 trial · 1 indication
Incidence of DLTs during the first 8 weeks (DLT evaluation window) after the first dose of LNTH-2403
Type, frequency, severity, timing, and relationship to LNTH-2403 of all Treatment-emergent adverse event, (TEAEs) and Serious adverse events, (SAEs)
Event-Free Survival (EFS) at 4 months
| Arm | Type | Description |
|---|---|---|
| Phase 1- Escalating doses of LNTH-2403 administered once every 8 weeks | EXPERIMENTAL | Phase 1 will evaluate escalating doses of LNTH-2403 administered once every 8 weeks, with the potential to explore other dosing schedules based on observed radiation dosimetry and PK parameters and safety and tolerability data. |
| Phase 2 will evaluate LNTH-2403 as a single agent at the recommended phase 2 dose | EXPERIMENTAL | Phase 2 will evaluate LNTH-2403 as a single agent in participants with R/R osteosarcoma at the recommended phase 2 dose (RP2D). |
| Name | Type | Description |
|---|---|---|
| LNTH2403 Phase 1 dose | DRUG | LNTH-2403 administered once every 8 weeks, with the potential to explore other dosing schedules based on observed radiation dosimetry and PK parameters and safety and tolerability data. |
| Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D). | DRUG | Once the RP2D is selected, phase 2 will commence |
Inclusion Criteria: Participants must meet all the following criteria to be enrolled in the study 1. Histopathologic documented diagnosis of R/R osteosarcoma 2. Must have disease characterized by at least one of the following (Participants meeting only (b.), only (c.), or only (b. and c.) must be d...
LNTH2403 Phase 1 dose is an investigational small molecule being studied for the treatment of relapsed or refractory osteosarcoma. It is currently in Phase 1 clinical development, with an active trial evaluating its safety and efficacy in patients with this condition.
LNTH2403 Phase 1 dose targets LRRC15, a protein involved in tumor biology. By targeting LRRC15, the drug aims to interfere with cancer cell processes, potentially offering a new therapeutic approach for patients with relapsed or refractory osteosarcoma.
LNTH2403 Phase 1 dose is being developed by Lantheus Holdings, Inc., a company traded under the ticker symbol LNTH. The company is conducting clinical research to evaluate this investigational therapy for relapsed or refractory osteosarcoma.
LNTH2403 Phase 1 dose is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities, and is currently being studied in a clinical trial for patients with relapsed or refractory osteosarcoma.
LNTH2403 Phase 1 dose is being evaluated in a Phase 1 clinical trial with the identifier NCT07357519, titled Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy). This trial is recruiting participants in the United States and aims to enroll 55 patients with relapsed or refractory osteosarcoma.
LNTH2403 Phase 1 dose is associated with the clinical trial Lu-TARGO, which stands for 177Lu-TARGeted Osteosarcoma Therapy. The trial NCT07357519 is evaluating this investigational drug in patients with relapsed or refractory osteosarcoma.